6980-11-6

Basic information

• Product Name: 7-chloro-1H-imidazo[4,5-b]pyridine
• Synonyms: 7-chloro-1H-imidazo[4,5-b]pyridine;7-Chloro-3H-imidazo[4,5-B]pyridine;7-Chloroimidazo[4,5-b]pyridine;7-Chloro-3H-imidazo[4,5-b...;3H-IMidazo[4,5-b]pyridine,7-chloro-
• CAS NO: 6980-11-6
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.56906
• Product Categories: Heterocycle-Pyridine series
• Mol File: 6980-11-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 396.465 °C at 760 mmHg
• Flash Point: 225.838 °C
• Appearance: /
• Density: 1.532 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.72
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO, Methanol
• PKA: 7.93±0.40(Predicted)
• CAS DataBase Reference: 7-chloro-1H-imidazo[4,5-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-chloro-1H-imidazo[4,5-b]pyridine(6980-11-6)
• EPA Substance Registry System: 7-chloro-1H-imidazo[4,5-b]pyridine(6980-11-6)

Safety Data

• Hazardous Substances Data: 6980-11-6(Hazardous Substances Data)

Usage

Uses

7-Chloro-3H-imidazo[4,5-b]pyridine is used as a reagent in the synthesis of purine derived S-adenosylhomocysteine/methylthioadenosine nucleosidase inhibitors which display antimicrobial activity. Also used as highly selective CYP3A4 inhibitors.

InChI:InChI=1/C6H4ClN3/c7-4-1-2-8-6-5(4)9-3-10-6/h1-3H,(H,8,9,10)

Upstream product

• 6863-46-3 Imidazo<4,5-b>pyridine 4-Oxide 
• 6863-46-3 3H-Imidazo<4,5-b>pyridine 4-N-oxide 
• 452-58-4 2,3-Diaminopyridine 
• 24484-98-8 4-chloro-2,3-diaminopyridine 
• 149-73-5 trimethyl orthoformate 
• 122-51-0 orthoformic acid triethyl ester 
• 273-21-2 3H-imidazo[4,5-b]pyridine 

Downstream Products

• 1230788-53-0 N-(1-(3-aminophenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)benzamide 
• 1230788-45-0 N-(3-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)-4-morpholino-3-(trifluoromethyl)benzamide 
• 1230788-51-8 N-(1-(3-nitrophenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)benzamide 
• 1374585-36-0 C₂₈H₂₀F₃N₅O₂ 
• 1374585-32-6 C₂₈H₁₉ClF₃N₅O₂ 
• 1374585-35-9 C₂₉H₁₉F₆N₅O₂ 
• 1384513-33-0 C₃₅H₃₄F₃N₇O₂ 
• 1374585-43-9 C₂₀H₁₅Cl₂N₅O 
• 1374585-42-8 C₂₁H₁₆F₃N₅O 
• 1374585-41-7 C₂₇H₁₈Cl₂N₄O₂ 
• 1374585-38-2 C₂₈H₁₉F₃N₄O₂ 
• 1374585-37-1 C₂₈H₁₈ClF₃N₄O₂ 
• 1374585-40-6 C₃₂H₂₃F₃N₆O₂ 
• 1374585-39-3 C₃₂H₂₆F₃N₅O₃ 

Relevant articles and documents

Heterocyclic compound as well as pharmaceutical composition, preparation method, intermediate and application thereof

The invention discloses a heterocyclic compound as well as a pharmaceutical composition, a preparation method, an intermediate and application thereof. The structure of the heterocyclic compound is shown as a formula I, and the heterocyclic compound has CDK7 inhibitory activity and can be used for treating diseases such as tumors.

Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2

A new series of diarylureas and diarylamides possessing 1H-pyrrolo[3,2-c]pyridine scaffold was designed and synthesized. Their in vitro antiproliferative activities against A375P human melanoma cell line and NCI-9 human melanoma cell line panel were tested. All the target compounds, except three amino derivatives 8g, h and 9h, demonstrated superior potencies against A375P to Sorafenib. In addition, compounds 8a and 9b-f demonstrated higher potencies than Vemurafenib against A375P. Compounds 8c and 9b were 7.50 and 454.90 times, respectively, more selective towards A375P melanoma cells over NIH3T3 fibroblasts. Furthermore, compounds 8d, e and 9a-d, f demonstrated very high potencies against the nine tested melanoma cell lines at the NCI. The bisamide derivatives 9a-c, f showed 2-digit nanomolar IC50 values over different cell lines of the NCI-9 melanoma cell lines.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.